Silo Pharma announced that it will exercise an option for an exclusive worldwide license to develop SPC-14, an intranasal therapy for the treatment of Alzheimer’s disease, from Columbia University. Silo says that it expects the license agreement to be finalized by mid-2024 and that it plans to pursue the 505(b)(2) regulatory pathway.
The company’s pipeline also includes SPC-15 intranasal ketamine, which Silo recently announced that it would license from Columbia University as well. In November 2023, Silo announced that it would use Medspray’s soft mist spray technology for delivery of SPC-15.
Silo CEO Eric Weisblum commented, “Columbia University has discovered a therapeutic candidate that could bring relief and hope for Alzheimer’s patients and families. In our opinion, available treatments for AD remain largely inadequate. We believe that the cognitive improvement and stress reduction shown by SPC-14 in preclinical studies could hold promise for this underserved disease market.”
Read the Silo Pharma press release.
